Fenwick & West represented Invenra, a leading biotechnology startup focused on developing therapeutic antibodies for the treatment of cancer, in its collaboration and license agreement with Exelixis (NASDAQ: EXEL). Through this collaboration, the companies will pair their respective technologies to discover and develop multispecific antibodies for the treatment of cancer. More information about this transaction can be obtained from Invenra’s press release.
The Fenwick transaction team was led by Stefano Quintini with support from technology transaction partner Jake Handy, patent partner Dan Becker and patent agent Zachery Newman.